- Conditions
- Cognitive Disorders, HIV Infections
- Interventions
- OPC 14117
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • New York, New York • Rochester, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 191
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dementia
- Interventions
- Otago Exercise Program
- Other
- Lead sponsor
- Marymount University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Arlington, Virginia
- Conditions
- Alzheimer Disease
- Interventions
- ACU193, Placebo
- Drug
- Lead sponsor
- Acumen Pharmaceuticals
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Anaheim, California • Newport Beach, California + 14 more
- Conditions
- Alzheimer Disease
- Interventions
- Seltorexant, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 25
- States / cities
- Tempe, Arizona • Lafayette, California • Homestead, Florida + 12 more
- Conditions
- Behavioral Variant Frontotemporal Dementia (bvFTD)
- Interventions
- TRx0237, Placebo
- Drug
- Lead sponsor
- TauRx Therapeutics Ltd
- Industry
- Eligibility
- Up to 79 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 24
- States / cities
- Los Angeles, California • Newport Beach, California • San Francisco, California + 21 more
- Conditions
- Alzheimer Disease
- Interventions
- ADEL-Y01 - healty participants, Placebo - Healthy Participants, ADEL-Y01 - MCI/AD, Placebo - MCI/AD
- Drug
- Lead sponsor
- Alzheimer's Disease Expert Lab (ADEL), Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Anaheim, California • Lady Lake, Florida • Maitland, Florida + 3 more
- Conditions
- Lewy Body Disease, Parkinson Disease
- Interventions
- E2027
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Sun City, Arizona • Atlantis, Florida • Miami, Florida + 10 more
- Conditions
- Mild Cognitive Impairment, Memory Disorders, Mild Dementia, Impaired Cognition, Mild Cognitive Disorder, Amnestic Disorder, Dementia and Amnestic Conditions, Poor Short-term Memory, Memory Impairment, Mild Neurocognitive Disorder
- Interventions
- Computerized brain fitness training, Yoga, Wellness Education, Support Group (patient and partner), Cognitive Rehabilitation
- Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Dementia With Lewy Bodies, Parkinson Disease Dementia, Healthy Controls
- Interventions
- Syn-One skin biopsy, Multi modal MRI, Assessment of dynamic EEG features over 48-hour periods across all study aims, Plasma biomarkers, Galantamine HBr extended-release 8mg capsules (8mg ER).
- Procedure · Diagnostic Test · Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Alzheimer's Disease
- Interventions
- AC-3933, Sugar Pill
- Drug · Other
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 34
- States / cities
- LIttle Rock, Alaska • Phoenix, Arizona • Little Rock, Arkansas + 27 more
- Conditions
- Parkinson Disease
- Interventions
- GRF6021, Placebo
- Drug · Other
- Lead sponsor
- Alkahest, Inc.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Englewood, Colorado • Doral, Florida + 15 more
- Conditions
- Dementia, Staff Attitude, Nurse's Role, Nursing Homes
- Interventions
- DIGNITY, Infection Control
- Behavioral
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- State College, Pennsylvania
- Conditions
- Alzheimer Disease
- Interventions
- Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers, Blood Biomarkers, Rating Scales, PU-AD, Placebo
- Radiation · Diagnostic Test · Behavioral + 1 more
- Lead sponsor
- Samus Therapeutics, Inc.
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 10
- States / cities
- Boca Raton, Florida • Delray Beach, Florida • Lake Worth, Florida + 6 more
- Conditions
- Asymptomatic Amyloid-positive
- Interventions
- Atabecestat, 5 mg, Atabecestat, 25 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 557 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more
- Conditions
- Mild Cognitive Impairment, So Stated
- Interventions
- AL-108, Placebo
- Drug
- Lead sponsor
- Allon Therapeutics
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 17
- States / cities
- Peoria, Arizona • Garden Grove, California • National City, California + 13 more
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Interventions
- AVP-786, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 387 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 111
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 78 more
- Conditions
- Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
- Interventions
- Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b
- Biological
- Lead sponsor
- AC Immune SA
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more
- Conditions
- Alzheimer's Disease With Vascular Pathology
- Interventions
- CY6463, Placebo
- Drug
- Lead sponsor
- Tisento Therapeutics
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Miami, Florida • Honolulu, Hawaii + 2 more
- Conditions
- Alzheimer's Disease
- Interventions
- GSK4527226, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 21
- States / cities
- San Diego, California • Lake Mary, Florida • Lake Worth, Florida + 16 more
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Parkinson Disease, Alzheimer Disease
- Interventions
- Focused Transcranial Ultrasound
- Device
- Lead sponsor
- Neurological Associates of West Los Angeles
- Other
- Eligibility
- 45 Years to 93 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- A Program of SUPPORT-D (dementia)
- Behavioral
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Alzheimer's Disease
- Interventions
- TRx0237 150 mg/day, TRx0237 250 mg/day, Placebo
- Drug
- Lead sponsor
- TauRx Therapeutics Ltd
- Industry
- Eligibility
- Up to 89 Years
- Enrollment
- 891 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Laguna Hills, California • Los Angeles, California + 23 more
- Conditions
- AIDS Dementia Complex, HIV Infections
- Interventions
- Abacavir sulfate
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 7
- States / cities
- San Diego, California • San Francisco, California • Baltimore, Maryland + 3 more
- Conditions
- Dementia Family Caregiver Burden and Conflict
- Interventions
- Telemental Health Family Intervention
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York